To whom does pharma turn when facing cutting-edge research challenges such as designing algorithms to comb unstructured EHR data hunting for undiagnosed pa
Via Richard Meyer
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
![]() ![]()
No comment yet.
Sign up to comment
Pharma Guy's curator insight,
December 14, 2016 2:27 PM
What about Instagram? Read “Pharma on Instagram”; http://sco.lt/4nv5LV
|
![]()
JEAN PASCAL POISSONNET's curator insight,
January 7, 2017 11:52 AM
Put the patient at the center of R and D regarding ways of developing mobile apps and involve health pros in the process : 2 golden rules applied by Pfizer, in order to market apps with true added value.
rob halkes's curator insight,
December 27, 2016 11:20 AM
Just discovered the global pharma reputation ranking by the Reputation Institute. Based on 7 dimensions of reputation, defined by the institute, the companies were evaluated by respondents around the world. These were "Products&Services, Innovation, Workplace,Governance, Citizenship, Leadership and Performance". See the RepTrak Institute here PatientView however has studied the global reputation of pharma companies in the perspective of patients and patient groups since 2011! See here. Their respondents were also distinguished by those who state to be familiar with a company and those who really worked with a company, which generates interesting data! PatientView is now preparing data such that companies can retrieve their bespoke ranking data to see how their reputation in the perspective of patients can further be improved
Pharma Guy's curator insight,
January 2, 2017 10:27 AM
NOTE: One trend pharmaceutical companies should take note of is the tendency of respondents to be uninformed or neutral about what companies actually do in certain areas. According to the survey, 12% of respondents did not have knowledge or opinion about the companies’ overall performance. Meanwhile, 11% had no knowledge of companies’ citizenship activities (promoting good causes and protecting the environment) and 14% didn’t know anything about the workplaces of the firms they were asked to score.
Pharma Guy's curator insight,
November 11, 2016 11:12 AM
Does this include "off-label" information? If so, I understand now why most pharma presenters at the recent FDA off-label hearing focused more on communicating off-label info to payers than to HCPs.
P.S. MSLs and KOLs are important sources of info for docs and these sources are controlled by pharma; i.e., not independent sources of information.
Pharma Guy's curator insight,
October 18, 2016 1:06 PM
Related article: “Johnson & Johnson Expands Its Membership in the Digital Innovation Club”; http://sco.lt/65ScEr |